Tags : Polyneuropathy of hATTR Amyloidosis

Alnylam’s Vutrisiran Receives the US FDA’s Fast Track Designation to

Shots: The US FDA has granted FT designation vutrisiran for treating polyneuropathy of hATTR amyloidosis in adults. The designation allows Alnylam to submit NDA for vutrisiran The P-I study assessing Vutrisiran (quarterly dosing with low-volume, SC) demonstrated a reduction in the burden of care for the disease. The safety & efficacy of the therapy are […]Read More